PFE Jun 2024 23.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:38PM EDT. Market open.
| Previous close | 4.1200 |
| Open | 4.1200 |
| Bid | 4.1500 |
| Ask | 4.2500 |
| Strike | 23.50 |
| Expiry date | 2024-06-21 |
| Day's range | 4.1000 - 4.1200 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
ZacksFDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Barrons.comSarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.
The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.
Investor's Business DailySarepta Catapults 39% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.
© 2024 Yahoo. All rights reserved.